Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Ground-breaking project scores Renewable Energy Award
2017-10-29

Description: ' 000 University Estates award Tags: University Estates award 

Marcel Theron, Former President: HEFMA; Nico van Rensburg, Senior Director:
University Estates (UFS); and Maureen Khati, Project Manager: Facilities
Planning (UFS) attending the HEFMA awards ceremony in Pretoria.
Photo: Supplied

University Estates at the University of the Free State (UFS) were recently awarded for their amazing initiative to install and operate photovoltaic (PV) and greywater systems on all three of its campuses. They were awarded by the Higher Education Facilities Management Association of Southern Africa (HEFMA), an association of facilities managers operating in the higher-education sector in the Southern African region. All universities and universities of technology in the country form part of this association, which promotes excellence in the planning, construction, maintenance, operations, and administration of educational facilities.

Nico van Rensburg, Senior Director of University Estates, says, “I want to thank HEFMA for this amazing award which motivates for much more and also opens up the doors for so many more opportunities.”

Solar and greywater systems installed at various buildings

In December 2016, 26 solar-driven LED street-light poles and a greywater system were installed at the Legae Residence on the South Campus. Greywater is made up of bath, shower, and bathroom sink water. The water is reused for toilet flushing, as well as for irrigation purposes.

On the Bloemfontein and Qwaqwa Campuses, the computer laboratories as well as the Thakaneng Bridge Student Centre and the expected Afromontane Research Centre have freestanding solar solutions mounted on their roofs. These systems are designed to operate independently of the power grid (Eskom) during sunlight hours when the PV solar panels are heated by the sun.

Teamwork equals ground-breaking results

“This was truly a team effort with a variety of role players who contributed,” says Van Rensburg. He believes that higher education can do more to make use of other environmentally sustainable initiatives, and to go beyond just erecting and renovating buildings.

The UFS executive management is also extremely proud of the team that were involved in the project. Prof Nicky Morgan, former Vice-Rector: Operations, says, “It’s been extraordinary what we could achieve at all three campuses with such a small team.” Nadeem Gafieldien, Director: Property Services at Stellenbosch University, showered the UFS with praise. “This is truly ground-breaking for Higher Education (HE) and you are truly leaders in these renewable energy projects in the HE sector.” He says we need to demonstrate to other institutions in the HE sector that this is the future and that it makes the institutions both environmentally and financially sustainable.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept